Skip to main content

Table 3 Adverse events during the follow-up period

From: Monitoring of efficacy, tolerability and safety of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial

Adverse eventALAS–AQ
Asthenia416
Loss of appetite22
Diarrhoea20
Vomiting12
Nausea01
Dizziness01
Hospitalizationa03
  1. aPneumonia, severe anaemia, and rhinotracheitis